New Veracyte/GE Partnership May Lead To Improved IPF Diagnosis

The molecular diagnostic company Veracyte, Inc. and the multinational conglomerate corporation GE have established a research partnership focused on developing novel solutions able to improve the diagnosis of diseases such as Idiopathic pulmonary fibrosis (IPF). The companies did not disclose the financial terms of the collaboration. Veracyte will work…

In a new study entitled “Plasticity of Hopx+ type I alveolar cells to regenerate type II cells in the lung,” researchers report a new unrecognized capacity of adult lung cells, type I cells, to revert into another cell type (type II cells), spurring on lung regeneration…

In a new study entitled “Tryptase is involved in the development of early ventilator-induced pulmonary fibrosis in sepsis-induced lung injury,” researchers identified mechanical ventilation as an inducer of pulmonary fibrosis by modulating secretion of pro-fibrotic factors. The study was published in the journal Critical…

A new study recently published in the journal The Lancet Respiratory Medicine revealed potential biomarkers for accurately assessing idiopathic pulmonary fibrosis (IPF) disease progression. The study is entitled “Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE…